Long-Term Use Of Pegaptanib In Patients For Subfoveal Choroidal Neovascularization Secondary To Age-Related Macular Degeneration

This study has been completed.
Information provided by (Responsible Party):
ClinicalTrials.gov Identifier:
First received: December 9, 2008
Last updated: September 30, 2015
Last verified: September 2015
The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3) factors considered to affect the safety and/or efficacy of this drug.

Condition Intervention
Macular Degeneration
Drug: Pegaptanib sodium

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Special Investigation For Long-term Use Of Macugen (Regulatory Post Marketing Commitment Plan).

Resource links provided by NLM:

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Factors considered to affect the safety and/or efficacy of this drug. [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
  • The incidence of adverse drug reactions in this surveillance. [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
  • Adverse drug reaction not expected from the LPD (unknown adverse drug reaction). [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]

Enrollment: 3538
Study Start Date: November 2008
Study Completion Date: February 2014
Primary Completion Date: February 2014 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Pegaptanib sodium
Patients administered Pegaptanib sodium.
Drug: Pegaptanib sodium

Macugen Intravitreous Injection Kit 0.3mg depending on the Investigator prescription.

Frequency and duration are according to Package Insert as follows. "Pegaptanib sodium is administered intravitreously once every 6 weeks at a dose level of 0.3 mg (on an oligonucleotide of pegaptanib basis )".

Other Name: Macugen

Detailed Description:
All the patients whom an investigator prescribes the first Macugen® should be registered consecutively until the number of subjects reaches target number in order to extract patients enrolled into the investigation at random.

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
The patients whom an investigator involving A5751033 prescribes the Macugen®).

Inclusion Criteria:

  • Patients need to be administered Macugen® in order to be enrolled in the surveillance.

Exclusion Criteria:

  • Patients not administered Macugen®.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00845273

Sponsors and Collaborators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
No publications provided

Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT00845273     History of Changes
Other Study ID Numbers: A5751033 
Study First Received: December 9, 2008
Last Updated: September 30, 2015
Health Authority: Japan: Pharmaceuticals and Medical Devices Agency

Keywords provided by Pfizer:
Subfoveal choroidal neovascularization secondary to age-related macular degeneration

Additional relevant MeSH terms:
Choroidal Neovascularization
Macular Degeneration
Neovascularization, Pathologic
Choroid Diseases
Eye Diseases
Pathologic Processes
Retinal Degeneration
Retinal Diseases
Uveal Diseases

ClinicalTrials.gov processed this record on February 08, 2016